Xenetic Biosciences Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Jeff Eisenberg
Chief executive officer
US$632.8k
Total compensation
CEO salary percentage | 63.9% |
CEO tenure | 6.4yrs |
CEO ownership | n/a |
Management average tenure | 6.9yrs |
Board average tenure | 5yrs |
Recent management updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$4m |
Sep 30 2023 | n/a | n/a | -US$4m |
Jun 30 2023 | n/a | n/a | -US$4m |
Mar 31 2023 | n/a | n/a | -US$6m |
Dec 31 2022 | US$633k | US$404k | -US$7m |
Sep 30 2022 | n/a | n/a | -US$7m |
Jun 30 2022 | n/a | n/a | -US$7m |
Mar 31 2022 | n/a | n/a | -US$6m |
Dec 31 2021 | US$750k | US$368k | -US$6m |
Sep 30 2021 | n/a | n/a | -US$5m |
Jun 30 2021 | n/a | n/a | -US$11m |
Mar 31 2021 | n/a | n/a | -US$11m |
Dec 31 2020 | US$446k | US$350k | -US$11m |
Sep 30 2020 | n/a | n/a | -US$11m |
Jun 30 2020 | n/a | n/a | -US$14m |
Mar 31 2020 | n/a | n/a | -US$14m |
Dec 31 2019 | US$603k | US$300k | -US$18m |
Sep 30 2019 | n/a | n/a | -US$19m |
Jun 30 2019 | n/a | n/a | -US$10m |
Mar 31 2019 | n/a | n/a | -US$11m |
Dec 31 2018 | US$318k | US$300k | -US$7m |
Sep 30 2018 | n/a | n/a | -US$1m |
Jun 30 2018 | n/a | n/a | -US$2m |
Mar 31 2018 | n/a | n/a | -US$3m |
Dec 31 2017 | US$815k | US$300k | -US$4m |
Compensation vs Market: Jeff's total compensation ($USD632.83K) is about average for companies of similar size in the US market ($USD662.11K).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
CEO
Jeff Eisenberg (57 yo)
6.4yrs
Tenure
US$632,827
Compensation
Mr. Jeffrey F. Eisenberg, also known as Jeff, Esq., has been the Chief Executive Officer of Xenetic Biosciences, Inc. since October 26, 2017; has been its Director since July 11, 2016 and also serves as it...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 6.4yrs | US$632.83k | no data | |
CFO, COO & Corporate Secretary | 6.9yrs | US$473.99k | 0% $ 0 | |
Chief Scientific Officer | 7.2yrs | US$470.37k | 0% $ 0 |
6.9yrs
Average Tenure
58yo
Average Age
Experienced Management: XBIO's management team is seasoned and experienced (6.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 7.7yrs | US$632.83k | no data | |
Independent Chairman of the Board | 6.6yrs | US$59.56k | 0% $ 0 | |
Independent Director | 8.1yrs | US$59.56k | 0% $ 0 | |
Independent Director | 10.2yrs | US$59.56k | 0% $ 0 | |
Independent Director | 6.6yrs | US$59.56k | 0% $ 0 | |
Non-Executive Director | less than a year | no data | 4.44% $ 272.5k | |
Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
Member of Scientific Advisory Board | 5.2yrs | no data | no data | |
Independent Director | 4.7yrs | US$59.56k | no data | |
Independent Non-Executive Director | 4.5yrs | US$59.56k | 0% $ 0 | |
Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
Member of Scientific Advisory Board | 1.8yrs | no data | no data |
5.0yrs
Average Tenure
56.5yo
Average Age
Experienced Board: XBIO's board of directors are considered experienced (5 years average tenure).